Page 9 - HFA_Dateline_2020_Q4_Winter

When it comes to your hemophilia A treatment

Move beyond the thresholda

Esperoct® can give you high factor levels for longer.b

Extend half-life beyond the standard 22-hour average half-life in adultsc

FOR ADULTS AND ADOLESCENTS

Switching made easy High factor levels Flexible on the go
with a standard 50 IU/kg dose every 4 days
At or above 3% The ONLY extended half-life
product that can be stored
-50% fewer infusions if you previously infused for 100% of the timed,e
up to 104°Fg
every other day At or above 5%
Please see Brief Summary for
-40% fewer infusions if you previously infused 3x a week for 90% of the timed,f complete storage instructions.

Safety Proven across 5 studies, the largest and longest EHL clinical trial program

aOf 1% trough factor levels for standard half-life (SHL) products in adults and adolescents.
bCompared with SHL products.
cData shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.
d Trough level goal is 1% for prophylaxis.
eData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days.
Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.
fSteady-state FVIII activity levels were estimated in 143 adults and adolescents using pharmacokinetic modeling.
gFor up to 3 months.

What is Esperoct®? What should I tell my healthcare provider before
Esperoct® [antihemophilic factor (recombinant), glycopegylated- using Esperoct®?
exei] is an injectable medicine to treat and prevent or reduce • Before taking Esperoct®, you should tell your healthcare
the number of bleeding episodes in people with hemophilia A.
Your healthcare provider may give you Esperoct® when you provider if you have or have had any medical conditions, take
have surgery any medicines (including non-prescription medicines and
dietary supplements), are nursing, pregnant or planning to
• Esperoct® is not used to treat von Willebrand Disease become pregnant, or have been told that you have inhibitors
to factor VIII
IMPORTANT SAFETY INFORMATION • Your body can make antibodies called “inhibitors” against
Esperoct®, which may stop Esperoct® from working properly.
Who should not use Esperoct®? Call your healthcare provider right away if your
• You should not use Esperoct® if you are allergic to factor VIII bleeding does not stop after taking Esperoct®
What are the possible side effects of Esperoct®?
or any of the other ingredients of Esperoct® or if you are • Common side effects of Esperoct® include rash or itching,
allergic to hamster proteins and swelling, pain, rash or redness at the location of infusion

What is the most important information I need to know Please see Brief Summary of Prescribing Information
about Esperoct®? on the following page.
• Do not attempt to do an infusion yourself unless you
Discover more at Esperoct.com.
have been taught how by your healthcare provider or
hemophilia treatment center

• Call your healthcare provider right away or get
emergency treatment right away if you get any signs of
an allergic reaction, such as: hives, chest tightness, wheezing,
dizziness, difficulty breathing, and/or swelling of the face

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro,
New Jersey 08536 U.S.A.

Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk Printed in the USA. US20ESP00014 February 2020